Regeneron Pharmaceuticals, Inc.’s decision to grant US President Donald Trump expanded access to its experimental cocktail of two monoclonal antibodies for COVID-19 could hinder the company’s clinical trials of the treatment and also the public’s broader appreciation of the need for such trials in the first place, experts warn, a move that could be disastrous for this pandemic and beyond.
Less than 24 hours after Trump tweeted that he tested positive for COVID-19, the White House announced on Friday 2...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)